Out of stock
ব্যবসার জন্য পাইকারি দামে পণ্য কিনতে রেজিস্টেশন করুন
Register
0 People recently viewed this
Pazonib
Drug International Ltd.
Generic: Pazopanib Hydrochloride
Safety Advices
বাংলা
English
CONSULT YOUR DOCTOR
It is not known whether it is safe to consume alcohol with Pazonib. Please consult your doctor.
CONSULT YOUR DOCTOR
Pazonib is unsafe to use during pregnancy as there is definite evidence of risk to the developing baby. However, the doctor may rarely prescribe it in some life-threatening situations if the benefits are more than the potential risks. Please consult your doctor.
UNSAFE
Pazonib is unsafe to use during breastfeeding. Data suggests that the drug may cause toxicity to the baby.
UNSAFE
Pazonib may decrease alertness, affect your vision or make you feel sleepy and dizzy. Do not drive if these symptoms occur.
SAFE IF PRESCRIBED
Pazonib is safe to use in patients with kidney disease. No dose adjustment of Pazonib is recommended.
CAUTION
Pazonib should be used with caution in patients with liver disease. Dose adjustment of Pazonib may be needed. Please consult your doctor.
Use of Pazonib is not advised in patients with moderate to severe liver disease.
Medicine Overview of Pazonib 200mg Tablet
Introduction
Pazonib is a protein kinase inhibitor used in the treatment of kidney cancer and soft tissue sarcoma. Pazonib should be taken on an empty stomach, but try to have it at the same time every day to get the most benefits. Your doctor will decide what dose is necessary and how often you need to take it. This will depend on what you are being treated for and may change from time to time. You should take it exactly as your doctor has advised. Taking it in the wrong way or taking too much can cause very serious side effects....
... Show moreUses of Pazonib
- Kidney cancer
- Soft tissue sarcoma
Side effects of Pazonib
Common
- Headache
- Nausea
- Vomiting
- Musculoskeletal (bone, muscle or joint) pain
- Fatigue
- Change in color of hair
- Diarrhea
- High blood pressure
- Decreased appetite
- Weight loss
- Taste change
- Abnormal skin pigmentation
- Hair discoloration
- Tumor pain
- Breathlessness
How to use Pazonib
Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Pazonib is to be taken empty stomach.
How Pazonib works
Pazonib is an anti-cancer medication. It works by binding and inhibiting the enzyme receptors (tyrosine kinase) that are responsible for the proliferation of the cancerous cells. It also restricts the growth of new blood vessels within the tumor. This is how it works against cancer.
Quick Tips
- Pazonib is used for the treatment of thyroid cancer.
- Take it with or without food, preferably at the same time each day.
- Diarrhea may occur as a side effect. Drink plenty of fluids and inform your doctor if it doesn't stop or if you find blood in your stools.
- Use a reliable contraceptive method to prevent pregnancy while you are taking this medicine and for a month after you stop taking it.
- Do not take it with medication lowering the stomach acid (such as antacids, H2 blockers including ranitidine), as it may affect the working of medicine.
- It may affect wound healing time. Be careful while shaving, cutting fingernails or toenails, or using sharp objects.
- Monitor your blood pressure regularly while taking this medication. Inform your doctor if you notice symptoms of very high blood pressure such as severe headache, confusion, problems with your eyesight, nausea or vomiting.
- Inform your doctor about the consumption of Pazonib before going for surgical procedure.
- It may cause serious bleeding problem. Inform your doctor if you get headaches, stomach pain or if you notice blood in your urine or stools.
- Do not take this medicine if you are pregnant, planning to conceive or breastfeeding.
Brief Description
Indication
Renal cell carcinoma, soft tissue sarcoma
Administration
Should be taken on an empty stomach: Take at least 1 hr before or 2 hr after meals. Swallow whole, do not break/crush.
Adult Dose
Advanced Renal Cell Carcinoma
800 mg PO qDay on empty stomach
Soft Tissue Sarcomas
800 mg PO qDay on empty stomach
Hepatic Impairment
Billirubin ULN: No dosage adjustment required
Billirubin >1.5-3 x ULN: Decreased dose to 200 mg PO qDay
Billirubin >3 x ULN: Not recommended
Child Dose
Safety and efficacy not established; not indicated for use in pediatric patients
Renal Dose
Renal impairment: No dosage adjustment required
Contraindication
Hypersensitivity.
Mode of Action
Multikinase inhibitor (including VEGF & PDGF receptor tyrosine kinases) some of which are implicated in tumor growth, angiogenesis, & metastasis
Precaution
Hepatic Toxicity and Hepatic Impairment, QT Prolongation, Cardiac Dysfunction, Hemorrhagic Events, Thromboembolic Events, Gastrointestinal Perforation and Fistula, Hypertension, Hypothyroidism, Pregnancy.
Lactation: Unknown whether distributed in breast milk, do not nurse
Side Effect
>10% ALT (SGPT) level raised (all grades, 53%; grade 3, 10%; grade 4, 2% ) AST/SGOT level raised (all grades, 53%; grade 3, 7%; grade 4, less than 1% ) Diarrhea (52%),Increased glucose (41%),Hypertension (40%),Hair depigmentation (38%) Leukopenia (all grades, 37%; grade 3, 0%; grade 4, 0% ) Increased bilirubin level (all grades, 36%; grade 3, 3%; grade 4, less than 1% ) Neutropenia (all grades, 34%; grade 3, 1%; grade 4, less than 1% ) Phosphorous decreased (34%) Thrombocytopenia (all grades, 32%; grade 3, less than 1%; grade 4, less than 1% ) Lymphocytopenia (all grades, 31%; grade 3,...
... Show moreInteraction
Co-administration w/ CYP3A4 (eg, itraconazole, clarithromycin, atazanavir, idinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole, grapefruit juice), P-gp & BCRP inhibitors, high-/low-fat food increases exposure & conc of pazopanib. Co-administration w/ CYP3A4 (eg, rifampicin) inducers may decrease plasma pazopanib conc. P-gp & BCRP inducers may alter exposure & distribution of pazopanib. Pazopanib may alter exposure &/or distribution of CYP3A4 substrates (eg, midazolam), CYP2C8 substrates (eg, paclitaxel) & UGT1A1 substrates (eg, irinotecan & its active metabolite SN-38). Pazopanib may increase the ratio of dextrometrophan to dextrophan conc after administration of dextrometrophan. Proton-pump inhibitors (eg, esomeprazole) & other agents that increase gastric pH...
... Show moreব্যবসার জন্য পাইকারি দামে পণ্য কিনতে রেজিস্টেশন করুন
Register
